A previous study reported that the expression of EZH2 promoted the progression of SCLC by suppressing the TGF-β-SMAD-ASCL1 pathway [35], while the expression of DLL3 was positively correlated with that of ASCL1 in SCLC [36]. This evidence concerns the gene DLL3 and small cell lung carcinoma.